Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 5

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 2
Chunk 5
---
 Goodwill and other intangible asset impairment charges276 33 243 — 243 0.16 Acquisition/divestiture-related net charges (credits)256 (59)315 — 315 0.21 Restructuring and restructuring-related net charges (credits)149 20 129 — 129 0.09 Investment portfolio net losses (gains) and impairments17 (0)17 — 17 0.01 EU MDR implementation costs39 5 34 — 34 0.02 Deferred tax expenses (benefits)— (120)120 — 120 0.08 Adjusted$3,065 $380 $2,685 $2 $2,683 $1.81 

43

Table of Contents

Quarterly Results and Business Overview 

The following section describes our net sales and results of operations by reportable segment and business. For additional information on our businesses and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K. 

 Three Months Ended September 30,(in millions)20252024Increase/(Decrease)Endoscopy$747 $678 10.1%Urology682 532 28.1%Neuromodulation293 268 9.1%MedSurg1,722 1,479 16.4%Cardiology2,641 2,129 24.0%Peripheral Interventions702 602 16.7%Cardiovascular3,343 2,731 22.4%Net Sales$5,065 $4,209 20.3%Nine Months Ended September 30,(in millions)20252024Increase/(Decrease)Endoscopy$2,157 $1,996 8.0%Urology1,992 1,570 26.9%Neuromodulation866 807 7.4%MedSurg5,015 4,373 14.7%Cardiology7,717 6,048 27.6%Peripheral Interventions2,056 1,765 16.5%Cardiovascular9,773 7,813 25.1%Net Sales$14,788 $12,186 21.4%

MedSurg

Endoscopy 

Our Endoscopy business develops